Despite an increased understanding of inflammatory bowel diseases (IBD) pathophysiology and the introduction of corresponding targeted treatments with the potential to alter the disease’s natural history, clinical and endoscopic remission remain elusive for many patients. Several factors contribute to suboptimal outcomes, including an entrenched treatment paradigm that frequently results in prolonged use of ineffective medications, uncertainty about the safety and efficacy of medications, systemic barriers, and access challenges.
In order to effectively treat IBD, gastroenterologists and the multidisciplinary IBD team of clinicians need strong foundational knowledge of the broad range of therapeutic agents licensed for the induction and maintenance of disease control, and how to individualize their use for any given patient. Education is necessary to ensure that clinicians who manage patients with IBD are up-to-date on current management strategies, including the use of objective measures such as mucosal healing and deep remission; new and emerging therapies, particularly novel mechanisms of action and safety profiles; and recent data from clinical trials. Clinicians must be knowledgeable regarding the benefits of early intervention, top-down versus step-up approaches, strategies for attaining remission and reducing healthcare costs, and new treat-to-target recommendations for management. This program will reduce these gaps through a conversational-style venue that fosters deeper educational impact and ultimately improves patient care.
Aline Charabaty Pishvaian, MD
Associate Professor of Medicine
Johns Hopkins School of Medicine
Clinical Director, GI Division
Director, IBD Center
Sibley Memorial Hospital
Washington, District of Columbia
Guarav Syal, MD
Assistant Professor of Medicine
Inflammatory Bowel Disease Center
Los Angeles, California
This educational initiative has been designed for all members involved in the IBD-care continuum. Of those that will derive the most benefit from this program are gastroenterologists, gastroenterologists in training, surgeons, subspecialists including dieticians and psychologists, nurse practitioners, physician’s assistants, nurses, and other healthcare team members involved in or interested in the care of patients with IBD.
Upon completion of this educational activity, participants will be able to:
There are no fees for participating and receiving CME credit for this activity. During the period of September 14, 2020 through September 14, 2021, participants must:
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.
Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Live Participation on September 14, 2020:
Integrity Continuing Education, Inc. designates this live material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation from September 15, 2020 – September 14, 2021:
Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or email@example.com.
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Aline Charabaty Pishvaian, MD
Consulting Fees: AbbVie, Janssen, Takeda
Speakers’ Bureaus: AbbVie, Takeda
Gaurav Syal, MD does not have any conflicts of interest to disclose.
The Integrity Continuing Education, Inc. planners/managers do not have any conflicts of interest to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)
Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Flash Player 10
Use of Internet Explorer browser is not recommended.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Provided by Integrity Continuing Education, Inc.
Supported by an educational grant from AbbVie Inc. Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.